Consumption analysis of two-component fixed combinations of medicines for arterial hypertension treatment in Ukraine as one of the stages for evaluation of their reimbursement prospects

Authors

DOI:

https://doi.org/10.15587/2519-4852.2022.263733

Keywords:

arterial hypertension, single pill combination, consumption patterns, reimbursement, pharmaceutical market

Abstract

The aim was to conduct a retrospective consumption analysis of 4 groups of single pill combinations for hypertension treatment and identify potential candidates for future inclusion in the reimbursement list in Ukraine, based on retrospective consumption patterns.

Materials and methods: The objects of the study were retail sales data in pharmaceutical market in Ukraine of four groups of single pill combinations used for arterial hypertension treatment. Data was provided by the marker research system “Pharmstandard” of the company of “Morion”. Analytic-comparative, systematic, logical, and mathematical-statistical methods were used.

Results: Single pill combinations of ACE inhibitors with diuretics were the most consumed among other combinations on 2018-2020. Retrospective evaluation of consumption patterns in period of 2018-2020 showed that combinations of captopril and hydrochlorothiazide (HCTD) 50 mg/25 mg, enalapril and HCTD 10 mg/25 mg, lisinopril and HCTD 10 mg/12.5 mg were the most consumed. Among ARB and diuretics combinations valsartan and HTCD (160 mg/12.5 mg and 80 mg/12.5 mg) and losartan and HTCD (50 mg /12.5 mg) were the most consumed among ARB and diuretics combinations. Within ACE inhibitors and calcium channel blockers (CCB) combinations the most consumed were lisinopril/amlodipine 10 mg/5 mg and a perindopril arginine/amlodipine 5 mg/5 mg. Valsartan and amlodipine holds the majority among ARC and CCB combinations, consumed in period of 2018-2020.

Conclusion: Apart from the single pill combinations, enlisted in the WHO Essential medicines list, eight more single pill combination were identified, based on retrospective consumption patterns, as potential candidates for further inclusion in the reimbursement list in Ukraine

Author Biographies

Anton Gonchar, Bogohomolets National Medical University

Postgraduate Student

Department of Pharmacy Organization and Economy

Nataliia Sholoiko, Bogohomolets National Medical University

PhD, Associate Professor

Department of Pharmacy Organization and Economy

References

  1. Nguyen, T. N., Chow, C. K. (2021). Global and national high blood pressure burden and control. The Lancet, 398 (10304), 932–933. doi: http://doi.org/10.1016/s0140-6736(21)01688-3
  2. Husain, M. J., Datta, B. K., Kostova, D., Joseph, K. T., Asma, S., Richter, P. et. al. (2020). Access to Cardiovascular Disease and Hypertension Medicines in Developing Countries: An Analysis of Essential Medicine Lists, Price, Availability, and Affordability. Journal of the American Heart Association, 9 (9). doi: http://doi.org/10.1161/jaha.119.015302
  3. Geldsetzer, P., Manne-Goehler, J., Marcus, M.-E., Ebert, C., Zhumadilov, Z., Wesseh, C. S. et. al. (2019). The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1·1 million adults. The Lancet, 394 (10199), 652–662. doi: http://doi.org/10.1016/s0140-6736(19)30955-9
  4. Chow, C. K. (2013). Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-Income Countries. JAMA, 310 (9), 959. doi: http://doi.org/10.1001/jama.2013.184182
  5. Rodgers, A., Chow, C. K., Jackson, R. T., Patel, A., Usherwood, T. (2017). Guideline for the diagnosis and management of hypertension in adults – 2016. Medical Journal of Australia, 206 (3), 141–141. doi: http://doi.org/10.5694/mja16.01057
  6. Gupta, P., Patel, P., Štrauch, B., Lai, F. Y., Akbarov, A., Gulsin, G. S. et. al. (2017). Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. Hypertension, 70 (5), 1042–1048. doi: http://doi.org/10.1161/hypertensionaha.117.09631
  7. Tiffe, T., Wagner, M., Rücker, V., Morbach, C., Gelbrich, G., Störk, S., Heuschmann, P. U. (2017). Control of cardiovascular risk factors and its determinants in the general population– findings from the STAAB cohort study. BMC Cardiovascular Disorders, 17 (1). doi: http://doi.org/10.1186/s12872-017-0708-x
  8. Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M. et. al. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 39 (33), 3021–3104. doi: http://doi.org/10.1093/eurheartj/ehy339
  9. Pro vnesennia zmin do nakazu Ministerstva okhorony zdorov’ia Ukrainy No. 751. 28.09.2012 (2016). Nakaz Ministerstva okhorony zdorov’ia Ukrainy No. 1422. 29.12.2016. Available at: https://zakon.rada.gov.ua/laws/show/z0530-17#Text
  10. Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M. et. al. (2020). Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. Journal of the American College of Cardiology, 76 (25), 2982–3021. doi: http://doi.org/10.1016/j.jacc.2020.11.010
  11. Jamison, D. T., Summers, L. H., Alleyne, G., Arrow, K. J., Berkley, S., Binagwaho, A. et. al. (2013). Global health 2035: a world converging within a generation. The Lancet, 382 (9908), 1898–1955. doi: http://doi.org/10.1016/s0140-6736(13)62105-4
  12. Su, M., Zhang, Q., Bai, X., Wu, C., Li, Y., Mossialos, E. et. al. (2017). Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. The Lancet, 390 (10112), 2559–2568. doi: http://doi.org/10.1016/s0140-6736(17)32476-5
  13. Attaei, M. W., Khatib, R., McKee, M., Lear, S., Dagenais, G., Igumbor, E. U. et. al. (2017). Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. The Lancet Public Health, 2 (9), e411–e419. doi: http://doi.org/10.1016/s2468-2667(17)30141-x
  14. Huz, V. S., Zaliska, O. M., Maksymovych, N. M. (2020). Retrospective analysis of prescriptions for the treatment of cardiovascular diseases in the program «Affordable medicines» on the example of a pharmacy. Farmatsevtychnyi Zhurnal, 3, 69–79. doi: http://doi.org/10.32352/0367-3057.3.20.07
  15. Piniazhko, O., Zaliska, O., Ilyk, R. (2018). Reimbursement Decision-Making in Ukraine: Current and Future Directions. Value in Health, 21, S107. doi: http://doi.org/10.1016/j.jval.2018.04.728
  16. Medicines reimbursement policies in Europe. World Health Organization. Regional Office for Europe. (‎2018)‎. World Health Organization. Regional Office for Europe. Available at: https://apps.who.int/iris/handle/10665/342220
  17. Huz, V. S., Zaliska, O. M. (2019). Analysis of dynamics of the drug list in the аffordable medicines program for treatment of cardiovascular diseases. Farmatsevtychnyi Zhurnal, 3, 21–30. doi: http://doi.org/10.32352/0367-3057.3.19.03
  18. eEML – Electronic Essential Medicines List (2019). World Health Organisation. Available at: https://list.essentialmeds.org/?section=&indication=139&year=2019&age=&sex=
  19. Pro vnesennia zmin do Natsionalnoho pereliku osnovnykh likarskykh zasobiv. (2021). Postanova Kabinety ministriv Ukrainy No. 1431. 23.12.2021. Available at: https://zakon.rada.gov.ua/laws/show/1431-2021-%D0%BF#Text
  20. Pro vnesennia zmin do Natsionalnoho pereliku osnovnykh likarskykh zasobiv (2017). Kabinet Ministriv Ukrainy postanova No. 1081. 13.12.2017. Available at: https://zakon.rada.gov.ua/laws/show/1081-2017-%D0%BF#Text
  21. WHOCC – Guidelines. 2022 Guidelines for ATC Classification and DDD Assigment (2021). WHO Collaboration Center for Drugs Statistics Methodology. Available at: https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/
  22. Doslidzhennia farmatsevtychnoho rynku Ukrainy analitychnoi kompanii “Farmstandart” kompanii “Morion”. Available at: http://pharmstandart.com.ua
  23. State register of medicines of Ukraine. Available at: http://www.drlz.com.ua/
  24. Sholoiko, N. V., Honchar, A. O. (2022). Comparative analysis of the range list of medicines for the treatment of arterial hypertension in accordance with domestic and international clinical guidelines. Farmatsevtychnyi Zhurnal, 1, 31–39. doi: http://doi.org/10.32352/0367-3057.1.22.03
  25. Osnovy statystyky ta analizu danykh (2019). Ukrainskyi tsentr suspilnykh danykh. Available at: https://socialdata.org.ua/manual/manual4/
  26. Lee, Y., Shin, J., Kim, Y., Kim, D.-S. (2021). Consumption of single products versus fixed-dose combination medicines for hypertension and hyperlipidemia during 2015–2019 in South Korea. PLOS ONE, 16 (12), e0259467. doi: http://doi.org/10.1371/journal.pone.0259467
  27. Ishida, T., Oh, A., Nishigaki, N., Tsuchihashi, T. (2019). Treatment patterns of antihypertensive fixed‐dose combinations according to age and number of agents prescribed: Retrospective analysis using a Japanese claims database. Geriatrics & Gerontology International, 19 (11), 1077–1083. doi: http://doi.org/10.1111/ggi.13743

Downloads

Published

2022-08-31

How to Cite

Gonchar, A., & Sholoiko, N. (2022). Consumption analysis of two-component fixed combinations of medicines for arterial hypertension treatment in Ukraine as one of the stages for evaluation of their reimbursement prospects. ScienceRise: Pharmaceutical Science, (4 (38), 19–27. https://doi.org/10.15587/2519-4852.2022.263733

Issue

No. 4 (38) (2022)

Section

Pharmaceutical Science

License

Copyright (c) 2022 Anton Gonchar, Natalia Sholoiko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.